Team, Inc. Reports Third Quarter Results SUGAR LAND, Texas,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Team, Inc. Reports Third Quarter Results

SUGAR LAND, Texas, April 7, 2014 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI ) today announced financial results for its fiscal year 2014 third quarter ending February 28, 2014. Team reported adjusted earnings of $0.01 per diluted share versus an adjusted loss of $0.01 per diluted share in the third quarter of the prior year. Revenues for the third quarter were $163 million compared to revenues of $151 million for the prior year quarter. Adjusted net income attributable to shareholders was $0.2 million, compared to an adjusted net loss available to shareholders of $0.2 million in the prior year quarter. The adjusted income for the current quarter excludes a $1.9 million pre-tax, non-routine charge associated with the Venezuelan currency revaluation announced in Team's press release issued on March 20, 2014. Team's earnings for the quarter as measured under generally accepted accounting principles, which includes this revaluation charge, was a loss of $0.05 per diluted share and a net loss attributable to shareholders of $1.0 million.

For the fiscal year to date, adjusted earnings were $0.86 per diluted share. Year to date revenues were $538 million and adjusted net income available to shareholders was $18.2 million.

"As indicated in our March 20 th release, we believe weather-related deferrals and disruptions reduced our revenues by about $6 million and our earnings by $0.10 to $0.12 per share in the third quarter," said Phil Hawk, Team's Chairman and Chief Executive Officer.

Highlights and other financial data for Third Quarter

  • Total revenue growth rates of 8% for the quarter and 5% year to date.
  • Quest revenues grew 43% in the quarter and have grown 19% year to date.
  • EBITDA (adjusted) of $7.3 million for the quarter and $76 million for the trailing twelve months.
  • Capital expenditures of $10 million for the quarter and $24 million year to date (including $2.7 million incurred in connection with the design phase of a new enterprise resource planning software system and $6.7 million for renovation of Team's Alvin, Texas facilities).
  • Net debt (total debt less cash) was $44 million at the end of the quarter.
  • Venezuelan asset revaluation (see below).

Fourth Quarter Earnings and Revenue Guidance

On March 20, 2014, Team announced that it expects fourth quarter earnings to be $0.65 to $0.80 per diluted share and fourth quarter revenues to be in the range of $210 million to $225 million; implying full year earnings (adjusted) in the range of $1.50 to $1.65 per diluted share and full year revenues between $750 million to $765 million.

Venezuelan Revaluation

Additionally, Team announced on March 20, 2014, that it has revalued the net assets of its Venezuelan business at the beginning of the third quarter, resulting in a $1.9 million non-routine, non-cash charge ($0.06 per share). Team also advised that additional revaluations are likely in the future as a Venezuelan state-run market based currency exchange has been put in place by the Central Bank of Venezuela.

Earnings Conference Call

In connection with this earnings release, Team will hold its quarterly conference call on Tuesday, April 8, 2014 at 8:00 a.m. Central Time (9:00 a.m. Eastern). The call will be broadcast over the Web and can be accessed on Team's Website, www.teamindustrialservices.com . Individuals wishing to participate in the conference call by phone may call 866-713-8563 and use conference code 80066122 when prompted.

About Team, Inc.

Headquartered near Houston, Texas, Team, Inc. is a leading provider of specialty industrial services, including inspection and assessment, required in maintaining and installing high-temperature and high-pressure piping systems and vessels that are utilized extensively in the refining, petrochemical, power, pipeline and other heavy industries. Team offers these services in over 125 locations throughout the world. Team's common stock is traded on the New York Stock Exchange under the ticker symbol "TISI".

Certain forward-looking information contained herein is being provided in accordance with the provisions of the Private Securities Litigation Reform Act of 1995. We have made reasonable efforts to ensure that the information, assumptions and beliefs upon which this forward-looking information is based are current, reasonable and complete. Such forward-looking statements involve estimates, assumptions, judgments and uncertainties. There are known and unknown factors that could cause actual results or outcomes to differ materially from those addressed in the forward-looking information. Such known factors are detailed in the Company's Annual Report on Form 10-K and in the Company's Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission, and in other reports filed by the Company with the Securities and Exchange Commission from time to time. Accordingly, there can be no assurance that the forward-looking information contained herein will occur or that objectives will be achieved.  We assume no obligation to publicly update or revise any forward-looking statements made today or any other forward-looking statements made by the company, whether as a result of new information, future events or otherwise.

TEAM, INC. AND SUBSIDIARIES
SUMMARY OF OPERATING RESULTS
(in thousands, except per share data)
         
  Three Months Ended Nine Months Ended
  February 28, February 28, 
  2014 2013 2014 2013
  (unaudited) (unaudited) (unaudited) (unaudited)
Revenues  $ 163,236  $ 150,975  $ 538,040  $ 513,115
Operating expenses  121,540  112,084  382,532  362,224
Gross margin  41,696  38,891  155,508  150,891
         
SG&A expenses  40,725  38,278  125,482  115,280
Earnings from unconsolidated affiliates  29  (4)  822  862
Gain from revaluation of contingent consideration  --   --   2,138  -- 
Operating income  1,000  609  32,986  36,473
         
Foreign currency loss   1,868  729  2,398  917
Interest expense, net  660  743  2,079  2,019
Earnings (loss) before income taxes  (1,528)  (863)  28,509  33,537
         
Provision for income taxes  (557)  (319)  10,406  12,409
Net income (loss) (971) (544) 18,103 21,128
         
Less: Income attributable to non-controlling interest 39 (9) 178  166
Net income (loss) available to shareholders  $ (1,010)  $ (535)  $ 17,925  $ 20,962
         
Earnings (loss) per common share:        
Basic  $ (0.05)  $ (0.03)  $ 0.88  $ 1.04
Diluted   $ (0.05)  $ (0.03)  $ 0.84  $ 0.99
         
Weighted average number of shares outstanding:        
Basic  20,384  20,387  20,432  20,104
Diluted   21,193  21,311  21,284  21,078
 
TEAM, INC. AND SUBSIDIARIES
ADDITIONAL FINANCIAL INFORMATION
(in thousands, except per share data)
         
  Three Months Ended Nine Months Ended
  February 28, February 28,
  2014 2013 2014 2013
  (unaudited) (unaudited) (unaudited) (unaudited)
Adjusted Net income:        
Net income (loss) available to common shareholders  $ (1,010)  $ (535)  $ 17,925  $ 20,962
Non-routine Venezuela currency devaluation  1,858  597  1,858  597
Non-routine revaluation of contingent consideration  --   --   (2,138)  -- 
Non-routine severance costs  --   --   742  -- 
Tax impact of adjustments  (678)  (221)  (173)  (221)
Adjusted Net income (loss)  $ 170  $ (159)  $ 18,214  $ 21,338
         
Adjusted Net income (loss) per common share:        
Basic  $ 0.01  $ (0.01)  $ 0.89  $ 1.06
Diluted  $ 0.01  $ (0.01)  $ 0.86  $ 1.01
         
Adjusted EBITDA:        
Operating income ("EBIT")  $ 1,000  $ 609  $ 32,986  $ 36,473
Non-routine revaluation of contingent consideration  --   --   (2,138)  -- 
Non-routine severance costs  --   --   742  -- 
Adjusted EBIT  1,000  609  31,590  36,473
Depreciation and amortization  5,285  4,800  15,976  14,454
Non-cash share-based compensation costs  995  902  3,205  3,022
Adjusted EBITDA  $ 7,280  $ 6,311  $ 50,771  $ 53,949
         
Segment Data:        
Revenues:        
IHT  $ 85,149  $ 81,227  $ 290,409  $ 272,372
MS  63,440  59,513  200,196  201,011
Quest  14,647  10,235  47,435  39,732
   $ 163,236  $ 150,975  $ 538,040  $ 513,115
         
Adjusted EBIT:        
IHT  $ 3,783  $ 4,439  $ 29,528  $ 30,411
MS  2,939  3,346  17,120  21,049
Quest  1,170  (62)  5,986  5,944
Corporate and shared support  (6,892)  (7,114)  (21,044)  (20,931)
   $ 1,000  $ 609  $ 31,590  $ 36,473
         
Adjusted EBITDA:        
IHT  $ 5,719  $ 6,305  $ 35,475  $ 36,115
MS  4,740  5,117  22,511  26,214
Quest  2,513  976  10,019  9,137
Corporate and shared support  (5,692)  (6,087)  (17,234)  (17,517)
   $ 7,280  $ 6,311  $ 50,771  $ 53,949
         
Revenues by Service Type:        
Inspection and assessment  $ 76,752  $ 71,347  $ 274,821  $ 247,664
Turnaround  48,150  41,869  144,354  157,877
On-stream services  38,334  37,759  118,865  107,574
   $ 163,236  $ 150,975  $ 538,040  $ 513,115
 
TEAM, INC. AND SUBSIDIARIES
SUMMARY CONSOLIDATED BALANCE SHEET INFORMATION
FEBRUARY 28, 2014 AND MAY 31, 2013
(in thousands)
     
  February 28, May 31,
  2014 2013
  (unaudited)  
     
Current assets  $ 235,400  $ 246,918
     
Property, plant and equipment, net  85,392  74,939
     
Other non-current assets  146,705  138,346
     
Total assets  $ 467,497  $ 460,203
     
Current liabilities  $ 60,606  $ 72,804
     
Long term debt net of current maturities  83,602  72,946
     
Other non-current liabilities  20,797  22,263
     
Stockholders' equity  302,492  292,190
     
Total liabilities and stockholders' equity  $ 467,497  $ 460,203
 
TEAM, INC. AND SUBSIDIARIES
SUMMARY CONSOLIDATED CASH FLOW INFORMATION
FEBRUARY 28, 2014 AND FEBRUARY 28, 2013
(in thousands)
     
  Nine Months Ended
  February 28,
  2014 2013
  (unaudited) (unaudited)
Net income  $ 18,103  $ 21,128
     
Depreciation, amortization and non-cash share based compensation expense 19,181 17,476
     
Gain on contingent consideration revaluation  (2,138)  --
     
Foreign currency loss 2,398 917
     
Working capital changes 2,511 (6,158)
     
Other items affecting operating cash flow (540) 4,853
     
Net cash provided by operating activities  $ 39,515  $ 38,216
     
Capital expenditures (23,758) (18,803)
     
Cash used for business acquisitions, net (10,175) (18,589)
     
Other items affecting investing cash flow 381 1,070
     
Net cash used in investing activities ($33,552) ($36,322)
     
Borrowings of debt, net 9,800 2,400
     
Purchases of treasury stock  (13,334)  --
     
Cash associated with share-based payment arrangements, net 4,165 9,727
     
Net cash provided by financing activities $631 $12,127
     
Effect of exchange rate changes (1,294) (76)
    .
Change in cash and cash equivalents  $ 5,300  $ 13,945

Ted W. Owen (281) 331-6154

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 421

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Updated Category News Views 281

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 34

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 536

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 462

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 547

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
2027 Toy of the Year Finalists Energize Play Market

Updated Category News Views 308

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 243

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading

Top 5 Most Recently Viewed Articles

Silexion Therapeutics to Showcase Innovations at Upcoming Conference

Updated Category News Views 127

Silexion Therapeutics and Its Future in Oncology Silexion Therapeutics Corp. is at the forefront of the biotechnology sector, focusing its efforts on innovative treatments specifically designed for oncology. This clinical-stage company is dedicated to transforming the landscape for patients with hard-to-treat cancers, primarily those with the mutated KRAS oncogene, known...

Continue Reading
UBS Predicts Slowdown in Nvidia-Led Tech Rally - Key Insights

Updated Category News Views 172

UBS Foresees Changes in Tech Rally Dynamics Analysts at UBS suggest that the excitement surrounding the recent tech rally, driven by Nvidia, is beginning to wane. They predict a shift towards a more volatile market environment, influenced by ongoing economic challenges and increasing regulatory scrutiny in the semiconductor sector. Analysts' Perspectives on Future Stock...

Continue Reading
OS Therapies (OSTX) Unveils Encouraging Survivorship Data

Updated Category News Views 222

OS Therapies Inc. Reports Promising Results in Bone Cancer Therapy OS Therapies Inc. (NYSE: OSTX), a company focused on developing innovative cancer treatments, recently reported compelling findings from its Phase 2b clinical trial on OST-HER2, an off-the-shelf immunotherapy designed for addressing osteosarcoma, a challenging form of bone cancer. Significant Survival Data...

Continue Reading
Jeito Capital Boosts Aviceda Therapeutics with $207.5M Funding

Updated Category News Views 239

Jeito Capital's Strategic Investment in Aviceda Therapeutics Jeito Capital has recently announced a significant investment in Aviceda Therapeutics, securing a substantial participation in an upsized $207.5 million Series C financing round aimed at advancing the company's lead program, AVD-104. This funding is specifically intended to support pivotal trials for AVD-104,...

Continue Reading
Apple's Innovative M4 Mac Mini Sets New Standards in Tech

Updated Category News Views 293

Apple Launches the Game-Changing Mac Mini Apple Inc (NASDAQ: AAPL) has once again captivated technology enthusiasts and consumers alike with its latest innovation — the redesigned Mac mini equipped with groundbreaking M4 and M4 Pro chips. This launch not only showcases Apple's commitment to performance but also its pioneering approach to sustainability, marking the Mac...

Continue Reading